Global Prostate Cancer Diagnostics Market $ 7.5 Billion

Dublin, June 18, 2021 (GLOBE NEWSWIRE) – The “Global Prostate Cancer Diagnostics Market Forecast by Type (Preliminary Screening, Confirmatory Testing, PCA3, Transrectal Ultrasound, Biopsy), End Users, Regions, Company Analysis” the report was added to ResearchAndMarkets.com offer.

Global prostate cancer diagnostics market to reach $ 7.5 billion by 2027, up from $ 1.6 billion in 2020

Experts forecast that the global Prostate Cancer Diagnostics market is expected to grow with a staggering double-digit CAGR of 24.69% during the period 2020-2027.

Early detection and treatment that improve the chances of survival is a paradigm in cancer treatment. Cancer, especially prostate cancer, has affected men more than women, the percentage being much lower than that of men. Our study investigated that prostate cancer is the second most common cancer in men in developed countries to date. At the same time, the incidence rate has also increased over time. According to the report,

In the past, prostate cancer was diagnosed with a DRE, which is a digital rectal exam and a PSA blood test, most commonly referred to as prostate specific antigen and TRUS, known as a transrectal ultrasound guided biopsy. . TRUS is the gold standard for confirming the diagnosis in all clinical circumstances today.

The most important factor in prostate cancer is age and is rare before the age of 40, and its incidence rate would increase with age. Thus, the factors that are fueling this market growth are the aging of the population and the high prevalence rate of prostate cancer. However, poor clinical trial success and high drug costs are the challenges facing this market.

In 2019, according to the Global Aging Population Report, 703 million people are aged 65 worldwide. It is expected to double by 2050 to reach 1.5 billion. In countries, several majors have been taken by government and regulatory bodies to beat this cancer in order to improve diagnostic options and expand treatment.

Among the regions, the most affected and highest prostate cancer cases are the North America region, followed by the Europe and Asia-Pacific regions.

The COVID-19 pandemic has transformed the market landscape. It has impacted almost every industry across countries due to restrictions, blockages, and bards on transportation. Many surgeries have been postponed due to this pandemic. And according to our study, there would be a sharp increase in this post-pandemic market recovery.

Discussed subjects :

1. Introduction

2. Research and methodology

3. Executive summary

4. Market dynamics
4.1 Growth drivers
4.2 challenges

5. Global Prostate Cancer Diagnostics Market

6. Market share analysis
6.1 Type of diagnosis
6.2 Confirmatory test
6.3 End user
6.4 Regions

7. Diagnosis Type – Global Prostate Cancer Diagnosis Market
7.1 Preliminary screening test
7.2 Confirmatory test
7.3 PCA3
7.4 Transrectal ultrasound
7.5 Biopsy

8. End User – Global Prostate Cancer Diagnostics Market
8.1 Hospitals and clinics
8.2 Diagnostic centers
8.3 Research institute
8.4 Others

9. Regions – Global Prostate Cancer Diagnostics Market
9.1 North America and Latin America
9.1.1 United States
9.1.2 Canada
9.1.3 Rest of America
9.2 Europe
9.2.1 Norway
9.2.2 Italy
9.2.3 Poland
9.2.4 Germany
9.2.5 United Kingdom
9.2.6 Rest of Europe
9.3 Asia
9.3.1 China
9.3.2 India
9.3.3 Rest of Asia
9.4 Africa
9.4.1 South Africa
9.4.2 Rest of Africa

10. Business analysis

• GSK
• AstraZeneca
• Sanofi
• Abbott
• Pfizer

For more information on this report, visit https://www.researchandmarkets.com/r/o3w7dc